NCT07062965
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07062965
Title A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Pfizer
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Highlands Oncology Group, PA NOT_YET_RECRUITING Fayetteville Arkansas 72703 United States Details
Highlands Oncology Group, PA NOT_YET_RECRUITING Rogers Arkansas 72758 United States Details
Highlands Oncology Group, PA NOT_YET_RECRUITING Springdale Arkansas 72762 United States Details
The University of Osaka Hospital RECRUITING Suita Osaka 565-0871 Japan Details
St. Luke's International Hospital RECRUITING Chuo-ku Tokyo 104-8560 Japan Details
The Cancer Institute Hospital of JFCR NOT_YET_RECRUITING Koto Tokyo 135-8550 Japan Details
Showa Medical University Hospital RECRUITING Tokyo 142-8666 Japan Details
Ad-Vance Medical Research NOT_YET_RECRUITING Ponce 00717 Puerto Rico Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field